Amphastar Pharmaceuticals Inc

For the period ended Dec 31, 2024. Filed Mar 3, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 3, 2025

AMPH$29.38+3.1%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations

(in thousands, except per share data)


	Year Ended December 31,
	2024		2023		2022
Net revenues:
Product revenues, net		$712,814		$593,238		$498,987
Other revenues		19,153		51,157		—
Total net revenues		731,967		644,395		498,987

Cost of revenues		358,112		293,274		250,127
Gross profit		373,855		351,121		248,860

Operating expenses:
Selling, distribution, and marketing		37,802		28,853		21,531
General and administrative		56,720		51,540		45,061
Research and development		73,914		73,741		74,771
Total operating expenses		168,436		154,134		141,363

Income from operations		205,419		196,987		107,497

Non-operating income (expenses):
Interest income		10,612		5,459		1,321
Interest expense		(30,343)		(27,158)		(1,846)
Other income (expenses), net		4,076		(3,929)		9,068
Total non-operating income (expenses), net		(15,655)		(25,628)		8,543

Income before income taxes		189,764		171,359		116,040
Income tax provision		29,672		31,833		23,477
Income before equity in losses of unconsolidated affiliate		160,092		139,526		92,563

Equity in losses of unconsolidated affiliate		(573)		(1,981)		(1,177)

Net income		$159,519		$137,545		$91,386

Net income per share:
Basic		$3.29		$2.85		$1.88

Diluted		$3.06		$2.60		$1.74

Weighted-average shares used to compute net income per share:
Basic		48,429		48,265		48,551

Diluted		52,058		53,001		52,427

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.